Non-invasive treatment for ALS using MyoRegulator® device

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility and safety of the MyoRegulator® device, which utilizes multi-site direct current stimulation (DCS) to treat individuals with Amyotrophic Lateral Sclerosis (ALS). Following a previous feasibility study, CALM aims to gather additional evidence on the device's effectiveness in slowing disease progression and improving motor function. The study will involve a single-arm, open-label design, focusing on ALS patients diagnosed within the last 24 months and assessing various clinical endpoints over a longer follow-up period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18-80 years of age inclusive
2. Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS as defined by revised El Escorial criteria
3. Less than or equal to 3 years since ALS symptom onset
4. Slow Vital Capacity ≥ 50% of predicted capacity at the time of Screening as determined using a portable spirometer
5. For TTNCS: Median CMAP ≥ 1.5 mV
6. Willing to forgo botulinum toxin, phenol or alcohol injections, intrathecal baclofen, digitalis, and morphine for the study duration
7. Willing to refrain from participation in any other therapeutic clinical trial or investigational product for ALS for the duration of this study
8. Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and 3 months after study completion.
9. Stable dose of rilutek (Riluzole), edaravone (Radicava), or tofersen (Qualsody) and oral medications for muscle spasms/cramps (e.g. mexiletine, quinine, quinidine, magnesium, gabapentin, oxcarbazepine, baclofen) for at least 30 days prior to the onset of participation in the study
10. ALS Functional Rating Score (ALSFRS-R) of greater than or equal to 35
11. Willing and able to give informed consent

Exclusion Criteria:

1. Study participants who are on permanent assisted ventilation (PAV) defined as \>22h of noninvasive or invasive ventilation a day for \> 7 consecutive days.
2. Study participants who have been diagnosed with ALS having only clinical bulbar involvement
3. Implanted intrathecal pump
4. Prior botulinum toxin injection(s) at any site within 12 weeks of study enrollment
5. Prior phenol or alcohol injections for spasticity within 6 months of study enrollment
6. Presence of potential tsDCS and/or TMS risk factors:

   1. Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)
   2. Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders
   3. Ferromagnetic metal in the head, neck or any site of stimulation including, but not limited to, aneurysm clips, implanted medication pumps, implanted brain stimulators, pacemakers, cochlear implants, implanted metal prostheses or metal due to any injury; dental fillings are permitted. Jewelry must be removed during stimulation
   4. Seizures or unexplained spells of loss of consciousness during the previous 12 months
   5. Any cardiac abnormality that may be exacerbated by transthoracic electrical stimulation
   6. History of cord lesions or previous spinal surgery that may interfere with procedure as determined by the study MD
   7. History of intracranial brain lesions, cortical stroke or previous neurosurgery that may interfere with TMS (e.g., in regions to be stimulated for TMS evaluations) as reviewed and approved by the study MD
7. Any medical condition that would prevent the participant from being able to participate in the clinical outcome measures
8. Pregnant females, as determined by a pregnancy test at V1 (in females of child-bearing potential)

Where it's running

• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Seward Rutkove (Clinical Site PI), M.D.
• Email: tokanlom@bidmc.harvard.edu
• Phone: 617-667-3083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tongue-strengthening exercises for people with ALS

  This program will test whether daily tongue-strengthening exercises can help people with ALS maintain or improve speech and swallowing.

  Recruiting Nova Southeastern University · Davie, Florida · NCT07295990

• Registering medical data and care outcomes for ALS, SMA, and other motor disorders

  This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.

  Recruiting Ambulanzpartner Soziotechnologie APST GmbH · Berlin, State of Berlin · NCT07900672

• Imaging markers for bulbar involvement in inclusion body myositis among IBM and comparison groups

  This study tests whether ultrasound and MRI can detect swallowing and bulbar muscle problems in people with inclusion body myositis.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07823101

• 7T MRI Pilot to Find Imaging Biomarkers in ALS and related motor neuron diseases

  A 7T MRI study is being done to see if ultra-high-field brain scans can reveal non-invasive biomarkers in adults with motor neuron disease, including ALS.

  Recruiting NHS Greater Glasgow and Clyde · Glasgow · NCT07818772

• Biomarker Repository for Age-Related and Inherited Neurodegenerative Diseases

  This study collects blood and genetic samples from people with neurodegenerative diseases and their families to build a shared resource for studying disease risk and biology.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07798700

• Ultra-high-resolution PET imaging of aging, neurodegeneration, and psychotic disorders

  We will test whether ultra-high-resolution PET and 3T MRI scans can reveal early brain and spinal cord changes in healthy adults and people with Alzheimer's, Parkinson's disease, ALS, PSP, REM sleep behavior disorder, or psychotic disorders.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaams-Brabant · NCT07509125

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.